133 STAT. 944  PUBLIC LAW 116–22—JUNE 24, 2019  (B) by inserting ‘‘and optimize’’ after ‘‘provide for’’;  (C) by inserting ‘‘and, as informed by existing rec- ommendations of, or consultations with, the Public Health  Emergency Medical Countermeasure Enterprise estab- lished under section 2811–1, make necessary additions or  modifications to the contents of such stockpile or stockpiles  based on the review conducted under paragraph (2)’’ before  the period of the first sentence; and  (D) by striking the second sentence;  (3) by inserting after paragraph (1) the following:  ‘‘(2) THREAT-BASED REVIEW.—  ‘‘(A) IN GENERAL.—The Secretary shall conduct an  annual threat-based review (taking into account at-risk  individuals) of the contents of the stockpile under para- graph (1), including non-pharmaceutical supplies, and, in  consultation with the Public Health Emergency Medical  Countermeasures Enterprise established under section  2811–1, review contents within the stockpile and assess  whether such contents are consistent with the recommenda- tions made pursuant to section 2811–1(c)(1)(A). Such review  shall be submitted on June 15, 2019, and on March 15  of each year thereafter, to the Committee on Health, Edu- cation, Labor, and Pensions and the Committee on Appro- priations of the Senate and the Committee on Energy and  Commerce and the Committee on Appropriations of the  House of Representatives, in a manner that does not com- promise national security.  ‘‘(B) ADDITIONS,  MODIFICATIONS,  AND REPLENISH- MENTS.—Each annual threat-based review under subpara- graph (A) shall, for each new or modified countermeasure  procurement or replenishment, provide—  ‘‘(i) information regarding—  ‘‘(I) the quantities of the additional or modified  countermeasure procured for, or contracted to be  procured for, the stockpile;  ‘‘(II) planning considerations for appropriate  manufacturing capacity and capability to meet the  goals of such additions or modifications (without  disclosing proprietary information), including  consideration of the effect such additions or modi- fications may have on the availability of such prod- ucts and ancillary medical supplies in the health  care system;  ‘‘(III) the presence or lack of a commercial  market for the countermeasure at the time of  procurement;  ‘‘(IV) the emergency health security threat or  threats such countermeasure procurement is  intended to address, including whether such  procurement is consistent with meeting emergency  health security needs associated with such threat  or threats;  ‘‘(V) an assessment of whether the emergency  health security threat or threats described in sub- clause (IV) could be addressed in a manner that  better utilizes the resources of the stockpile and  permits the greatest possible increase in the level  Assessment.  Deadlines.  Assessment.  Consultation. 